Can cisplatin and etoposide be administered via a peripheral intravenous line for the first chemotherapy cycle?

Peripheral Line Administration of Cisplatin and Etoposide for Cycle 1

Yes, cisplatin and etoposide can be safely administered through a peripheral intravenous line for the first chemotherapy cycle, and in fact, peripheral IV access may be preferable to central venous access devices (CVADs) for the entire treatment course in patients receiving these agents for germ cell tumors.

Evidence Supporting Peripheral IV Use

The most compelling evidence comes from a 2024 retrospective study of 154 testicular cancer patients receiving first-line chemotherapy 1. This study demonstrated that peripheral IV access was well-tolerated with significantly lower complication rates compared to CVADs:

• Only 9.7% of patients starting with peripheral IV needed to transition to CVADs during therapy
• The CVAD group experienced substantially higher rates of venous access-related complications (52.2% vs. peripheral IV group, p<0.001)
• Thrombotic events occurred in 35.9% of CVAD patients compared to significantly fewer in the peripheral IV group (p<0.001)
• Peripheral IV allowed high rates of therapy completion

Drug Administration Specifications

According to FDA labeling, cisplatin must be administered as a slow intravenous infusion over 6-8 hours, never as a rapid IV injection 2. The standard dosing for germ cell tumors is:

• Cisplatin: 20 mg/m² IV daily for days 1-5 per cycle 3
• Etoposide: 100 mg/m² IV daily for days 1-5 per cycle 3

The cisplatin infusion requires dilution in 2 liters of 5% dextrose in 1/2 or 1/3 normal saline containing 37.5g of mannitol, with pretreatment hydration of 1-2 liters over 8-12 hours 2.

Key Considerations for Peripheral Administration

Vesicant properties: Neither cisplatin nor etoposide are classified as vesicants at standard concentrations. However, cisplatin solutions with concentrations >0.5 mg/mL can cause local tissue toxicity including cellulitis, fibrosis, and necrosis if extravasation occurs 2. When properly diluted per FDA guidelines (in 2 liters of fluid), the concentration remains well below this threshold.

Infusion duration: The prolonged 6-8 hour infusion time for cisplatin actually makes peripheral administration more feasible, as the slow rate reduces vein irritation.

Monitoring requirements: Close observation during infusion is essential to detect early signs of extravasation, particularly during cycle 1 when vein tolerance is being established.

When to Consider Central Access

While peripheral IV is preferred, certain situations warrant consideration of CVADs from the outset:

• Poor peripheral venous access at baseline
• History of difficult IV access
• Concurrent administration of other vesicant agents
• Patient preference after informed discussion of risks

However, the evidence suggests these should be exceptions rather than routine practice 1.

Practical Algorithm

For Cycle 1:

1. Assess peripheral veins - if adequate, proceed with peripheral IV
2. Ensure proper dilution per FDA guidelines (concentration <0.5 mg/mL)
3. Administer with close monitoring for extravasation
4. Maintain adequate hydration before, during, and after infusion

For subsequent cycles:

• Continue peripheral IV if cycle 1 tolerated well
• Only transition to CVAD if complications develop (phlebitis, extravasation, access failure)

This approach aligns with the finding that only 10% of patients needed to change their initial access method during treatment 1, supporting the safety and feasibility of starting and continuing with peripheral access when appropriate.